This webinar discusses the critical factors involved in amyloid light chain (AL) amyloidosis diagnosis, prognosis and management, describing both haematologic and organ responses to treatment. The presentation also delves into the origins of cardiac amyloidosis, outlining investigations required to assess organ involvement and establish a diagnosis.
Themes covered include:
- diagnostic investigations for suspected amyloidosis and for confirmation of AL amyloid
- prognostic factors, treatment options, and toxicity for AL amyloid
- the importance of teamwork in the treatment landscape supportive management for AL amyloidosis
- the importance of adequate haematological response, and insight into monitoring typical slow organ response.
Speaker:
Guy Pratt has been a Consultant Haematologist in Birmingham, UK, since 2001, with a clinical and research interest in multiple myeloma, Waldenstrom macroglobulinaemia, and related plasma cell disorders. He is Professor of Haematology at the University of Birmingham. He was Clinical Lead for the 2016 National Institute for Health and Care Excellence (NICE) myeloma guidelines, and holds a number of positions nationally, including British Society for Haematology (BSH) Guideline Lead for Haemato-Oncology, Chair of the BSH Science and Publication Committee, and Secretary for the UK Myeloma Forum. He is currently a trustee for two charities, Cure Leukaemia and Waldenstroms Macroglobulinaemia UK (WMUK).
